AmCAD-UV

by AmCad BioMed  · Based in Taiwan → — Pioneering Ultrasound AI The Future of Ultrasound Imaging is Here
Cardiology Radiology Vascular Surgery

Regulatory Status Disclosed

Overview

AmCAD-UV is a software device developed by AmCad BioMed Corporation, specializing in AI-powered ultrasound solutions for medical diagnostics. The tool displays noise-reduced, color-coded pulsatile signals, which can assist users in interpreting variations in the hemodynamic properties of blood vessels. AmCAD-UV functions as a general-purpose medical image processing tool for vascular pulsatility analysis and is intended for prescription use. It is important to note that it must not be used alone for primary diagnostic interpretation. The software processes dynamic flow Doppler ultrasound images in DICOM, Bitmap, or JPEG formats and is compatible with Windows XP or higher operating systems, including Windows Embedded and DICOM-compliant medical devices.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • Quantifies and classifies ultrasonic color intensity data
  • Displays noise-reduced color-coded pulsatile signals
  • Differentiates between pulsatile signals and noise
  • Simultaneously displays quantified intensities of differentiated signals
  • User-friendly interface for setting signal detection sensitivity
  • Exports quantified values in text format
  • Exports color-coded pulsatile images and waveform trend charts in Bitmap format
  • Displays dynamic intensity information as color-coded images
  • Enhances contrast and reduces noise in images
  • Utilizes proprietary algorithms for noise reduction

Use Cases

  • Assisting interpretation of hemodynamic property variations in blood vessels
  • Vascular pulsatility analysis using flow Doppler ultrasound images
  • General-purpose medical image processing for ultrasound diagnostics

What Physicians Need to Know

ECG/EKG Analysis Capability
AmCAD-UV is showcased for cardiology with deep-learning-based ECG analysis. An EKG measures the electrical activity of the heartbeat and is used to diagnose and monitor various heart conditions, including arrhythmia, cardiomyopathy, congenital heart defects, coronary artery disease, heart attack, and heart failure. AI-based analysis of Holter recordings has shown to be faster and at least as accurate as conventional analysis by electrophysiologists. Additionally, 1-lead ECGs from smartwatches can predict left ventricular function with accuracy comparable to 12-lead ECGs, especially when combined with interpretable AI.
Echocardiography AI Features
AI in echocardiography has evolved to include automated segmentation, view classification, auto measurements, and AI-generated reports and diagnoses. AI tools can interpret echocardiograms with high accuracy in minutes, performing diagnostic tasks and detecting conditions like severe aortic stenosis, systolic dysfunction, and left ventricle ejection fraction. AI algorithms can match expert performance in key echocardiographic assessments, enhancing efficiency and consistency. AmCAD-UV is an AI solution that quantifies and visualizes ultrasound image features to help physicians make informed decisions.
Cardiac CT/MRI Analysis
AI is being used to analyze cardiac magnetic resonance (CMR) images and ECGs with deep learning to identify patients at high risk of sudden death. AI algorithms can analyze MRI studies to improve outcomes for heart failure patients needing cardiac resynchronization therapy (CRT), identifying optimal lead placement for pacemakers or defibrillators. AI-guided cardiovascular image analysis can accurately and reliably identify and quantify cardiovascular risk from electrocardiograms, echocardiograms, computed tomography, and cardiac magnetic resonance imaging. Cardiac computed tomography angiography (CCTA) is a promising tool for non-invasive assessment of compositional and structural changes in coronary arteries and for risk stratification of patients with coronary artery disease. Ultrahigh-spatial-resolution photon-counting detector CT (PCD-CT) improves the assessment of coronary artery disease, potentially leading to reclassification to a lower disease category and reducing unnecessary interventions.
Heart Failure Risk Prediction
Machine learning algorithms are used for heart failure risk stratification, with some models achieving high accuracy. Risk prediction models for heart failure have been developed and validated, incorporating factors like age, sex, and treatment-related factors. AI pipelines can predict the risk of heart failure using large-scale electronic health record (EHR) databases, offering state-of-the-art performance and insights into risk factors. The Framingham Heart Study recommends the 2018 ASCVD 10-year Risk Calculator to estimate cardiovascular disease risk, using information such as age, sex, race, cholesterol levels, blood pressure, diabetes status, and smoking status.
Coronary Artery Assessment
Coronary computed tomography angiography (CCTA) is a non-invasive imaging modality used to improve diagnostic discrimination for chest pain and assess coronary artery disease (CAD). CCTA can show plaque deposits and identify the type of plaque (hard, calcified, or soft, fatty deposits) and blockages. AI integration with imaging, including cardiac CT, enables automated chamber quantification, myocardial strain analysis, valve assessment, and plaque characterization. AmCAD-UV is a Doppler Ultrasound Pulsatile Signal Analysis and Visualization Platform. It is designed for quantifying and classifying ultrasonic color intensity data from FDA-cleared ultrasound systems, displaying noise-reduced color-coded pulsatile signals that may assist in interpreting variations in hemodynamic properties of blood vessels.
AHA/ACC Guideline Alignment
The American College of Cardiology (ACC) and American Heart Association (AHA) produce clinical guidelines and policies for high-quality cardiovascular care. Guidelines cover topics such as the evaluation and diagnosis of chest pain, management of chronic coronary disease, and acute coronary syndromes. These guidelines provide evidence-based recommendations for clinicians.
Physician Tip

AmCAD-UV offers AI-powered Doppler ultrasound pulsatile signal analysis and visualization, which can be a valuable tool for assessing hemodynamic properties of blood vessels. The system's ability to quantify and classify ultrasonic color intensity data could aid in the interpretation of blood flow variations. Physicians should integrate this tool to enhance their diagnostic capabilities in cardiovascular assessments, particularly where detailed pulsatile signal analysis is beneficial. The deep-learning-based ECG analysis capability can assist in identifying various cardiac conditions and arrhythmias. Leveraging AI for echocardiogram interpretation can significantly reduce analysis time and improve accuracy for conditions like aortic stenosis and left ventricular dysfunction. Furthermore, the potential for AI to analyze cardiac CT/MRI data for risk stratification and heart failure prediction offers advanced insights for personalized patient management. Adherence to AHA/ACC guidelines remains crucial when incorporating these AI tools into clinical practice.

AmCAD-UV is a software device that processes ultrasonic color intensity data acquired from FDA-cleared ultrasound systems. AmCad BioMed has integrated its AI ultrasound technology with major international Point-of-Care Ultrasound (POCUS) manufacturers to develop handheld devices with real-time AI diagnostic and analysis capabilities. This suggests potential for integration with various ultrasound hardware platforms. The platform is compatible with various recording formats, allowing the use of a single software for different Holters or patches. The broader field of cardiovascular AI emphasizes the need for data interoperability among ambulatory medical devices, sensors, and software applications to facilitate innovation in preventing and treating cardiovascular disease.

Details

Category Cardiology AI, Radiology & Imaging AI
Pricing Unknown
DeploymentAmCAD-UV is a software device. AmCAD-UT is a Windows-based computer-aided detection (CADe) device. AmCAD-US is a software device for tablet PC deployment.
Compliance
BAA AvailableUnknown
HIPAA CompliantUnknown
FDA Status Cleared AI-estimated
Integrations
EHR Not specified
Specialties Cardiology, Radiology, Vascular Surgery

FDA clearance history

This product’s FDA authorization. From FDA’s list of AI-enabled medical devices; each number links to FDA’s record.

Decision dateNumberName as listed by FDA
2017-04-26K170069 510(k)AmCAD-UV

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate AmCAD-UV

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money
No press coverage or publications on file yet. Know of some? Suggest an edit →

Videos

Product demos, reviews, and walkthroughs for AmCAD-UV.

Loading videos...

View all on YouTube

Frequently Asked Questions

AmCAD-UV is an AI-powered ultrasound imaging software developed by AmCad BioMed Corporation. While AmCad BioMed specializes in AI ultrasound solutions for various medical diagnostics, including thyroid nodules and obstructive sleep apnea, the specific application of "AmCAD-UV" in cardiology is for classifying ultrasonic color intensity data from flow Doppler ultrasound images.
AmCad BioMed Corporation holds multiple FDA and CE certifications for its AI-powered ultrasound solutions. While the specific regulatory status of AmCAD-UV for cardiology applications isn't detailed, other AmCAD products, like AmCAD-UT, are FDA-cleared as computer-aided detection (CADe) devices intended to assist medical professionals in analyzing ultrasound images.
Yes, the field of AI in cardiology is rapidly expanding with numerous alternatives. Many companies are developing AI-powered devices and software to improve diagnostic capabilities, patient outcomes, and clinical workflows in cardiology, including solutions for ECG analysis, echocardiography, cardiac CT, and cardiac MRI. Examples include AI-enhanced focused cardiac ultrasound (FoCUS) for detecting reduced left ventricular function and valvular disease, and AI for analyzing ECGs to detect conditions like reduced left ventricular ejection fraction (LVEF) and aortic stenosis.
General limitations of AI in cardiology include the incremental rather than transformative clinical impact, with limited evidence of improved patient outcomes or cost-effectiveness. Challenges also exist in the generalizability of AI models, ethical considerations, data privacy, data quality issues, and potential biases in algorithms. While AmCAD-UV aims to enhance diagnostic accuracy, these broader AI limitations could apply, emphasizing that AI is a tool to augment clinical expertise rather than replace it.
Information regarding the specific pricing model for AmCAD-UV is not publicly available. Pricing for medical AI tools can vary significantly based on factors such as features, integration capabilities, and licensing agreements.

Related Tools

Stethophone Pro
Sparrow Acoustics
Cardiology AI
Stethophone Pro transforms smartphones into advanced cardiac screening tools, enabling clinicians to capture, interpret, and visualize heart sounds for early detection of cardiovascular diseases.
ACUSON Sequoia Diagnostic Ultrasound System, ACUSON Sequoia Select Diagnostic Ultrasound System, ACUSON Origin Diagnostic Ultrasound System, ACUSON Origin ICE Diagnostic Ultrasound System
Siemens Medical Solutions, USA
Cardiology AI
Siemens Healthineers offers advanced AI-powered ultrasound systems, including the ACUSON Origin for comprehensive cardiovascular care and the ACUSON Sequoia for high-performance general imaging with BioAcoustic™ technology.
syngo.via MI Workflows, syngo MBF
Siemens Medical Solutions USA
Cardiology AI
syngo.via MI Workflows, syngo MBF is an intelligent, integrated imaging software that helps address the challenges of interpreting, managing, and sharing complex data from molecular imaging scanners, providing automated workflows and advanced visualization for various clinical applications.
syngo.via MI WorkFlows, Scenium, syngo MBF
Siemens Medical Solutions USA
Cardiology AI
syngo.via MI Workflows, Scenium, and syngo MBF are medical diagnostic post-processing applications for viewing, manipulation, quantification, analysis, and comparison of PET or nuclear-medicine functional data with CT or MR anatomical data across timepoints, supporting disease management and radiotherapy treatment planning by trained healthcare professionals.
ACUSON Sequoia Diagnostic Ultrasound System, ACUSON Sequoia Select Diagnostic Ultrasound System, ACUSON Origin Diagnostic Ultrasound System
Siemens Medical Solutions USA
Cardiology AI
Siemens Healthineers offers the ACUSON Sequoia, ACUSON Sequoia Select, and ACUSON Origin ultrasound systems, providing advanced imaging for various medical needs. The Sequoia line focuses on high-resolution imaging with deep penetration and reduced variability, while the AI-powered ACUSON Origin specializes in comprehensive cardiovascular diagnostics and interventions.
R30 Diagnostic Ultrasound System
Samsung Medison Co.
Cardiology AI
The Samsung Medison R30 Diagnostic Ultrasound System is a general-purpose, mobile, software-controlled diagnostic ultrasound system that offers a wide range of imaging capabilities and analysis tools for various clinical applications.

See all Cardiology AI tools →

More from AmCad BioMed

AmCAD-UO
AmCad BioMed Corporation
Radiology & Imaging AI
AmCAD-UT
AmCad BioMed Corporation
Endocrinology & Metabolic AI

View company profile →

Suggest an Edit → | Report an issue | Last Verified: 2026-10-14 | First Added: 2026-04-17
AI Tool Finder
AI-powered search. Results may not be comprehensive.